ANCA-Associated Vasculitis

This is a type of inflammation in your blood vessels. It's caused by certain antibodies that attack your body's white blood cells called neutrophils. This inflammation damages small and medium-sized blood vessels throughout your body. It can lead to various problems depending on which blood vessels are affected.

Condition

What people with ANCA-Associated Vasculitis report

Every report comes from a Lived member, sent anonymously.

Have you tried Rituximab for ANCA-Associated Vasculitis?

NameHow it went

About ANCA-Associated Vasculitis

What It Is

ANCA-associated vasculitis is a group of rare autoimmune diseases in which the immune system inflames and damages small blood vessels. Because small vessels supply nearly every organ, the effects can show up almost anywhere, most often in the kidneys, lungs, sinuses and ears, eyes, skin and nerves. Many people first notice fatigue, fever, night sweats, weight loss or aching muscles and joints, along with symptoms from whichever organs are involved. ANCA stands for anti-neutrophil cytoplasmic antibodies, proteins in the blood that target a type of white blood cell. The group has three main forms. Granulomatosis with polyangiitis (GPA, once called Wegener's granulomatosis) often affects the nose, sinuses, lungs and kidneys. Microscopic polyangiitis (MPA) most often affects the kidneys and lungs. Eosinophilic granulomatosis with polyangiitis (EGPA, once called Churg-Strauss syndrome) usually follows adult-onset asthma and sinus problems and involves high levels of eosinophils, a type of white blood cell linked to allergy. These diseases are serious because inflamed vessels can bleed or close off, and the organ damage this causes can become permanent. Recognized and treated promptly, most people reach remission, a period when the disease is no longer active.

Causes & Risk Factors

Researchers do not know exactly what sets off ANCA-associated vasculitis. Most people with ANCA-associated vasculitis have ANCA in their blood, and these antibodies appear to drive the inflammation, but some people with the antibodies never develop vasculitis, and some people with vasculitis test negative for them. Age is the strongest known risk factor. The diseases can begin at any age, including childhood, but they become steadily more common in older adults. Inherited and environmental factors also play a part, though in most people no specific trigger is found. A small number of cases are linked to particular exposures, including hydralazine (a blood pressure medicine), propylthiouracil (a thyroid medicine) and cocaine. In those cases, stopping the exposure is part of treatment.

How It's Diagnosed

No single symptom or test diagnoses ANCA-associated vasculitis. A clinician looks for a pattern of inflammation affecting more than one part of the body, such as persistent sinus trouble, a cough or breathlessness, numbness or weakness, and abnormal kidney tests. Because each symptom on its own can look like something common, such as sinusitis or asthma, the diagnosis is often delayed until someone connects the pieces. Urine tests are an important early step. Blood or protein in the urine, with a rising level of creatinine (a waste product the kidneys normally clear), can signal kidney inflammation, which often causes no symptoms until it is advanced. Blood tests look for inflammation, anemia and kidney function, and a chest X-ray or CT scan checks the lungs. The ANCA blood test strengthens the diagnosis when the overall picture fits, and it usually identifies which of two target proteins the antibodies attack (PR3 or MPO). PR3 antibodies are more typical of GPA, which tends to relapse more often, and MPO antibodies of MPA. It is not proof on its own: some people with vasculitis test negative, and infections, cancer and other conditions can cause a positive result. A biopsy, a small tissue sample from the kidney, lung, nose or skin, often confirms the diagnosis and rules out look-alikes such as infection or cancer. Care is usually led by a rheumatologist, nephrologist (kidney specialist) or specialist vasculitis team.

Treatment Options

Treatment works in two phases. The first, called induction, aims to switch off active inflammation quickly to protect the organs. The second, called maintenance, aims to keep the disease in remission and prevent relapse. For GPA and MPA, induction usually combines a corticosteroid such as prednisone with either rituximab (Rituxan, or a biosimilar), an antibody infusion that removes B cells, the immune cells that give rise to ANCA-making cells, or cyclophosphamide, an immune-suppressing medicine also used at higher doses in cancer care. Both work about equally well for new disease, and rituximab is generally preferred after a relapse. Cyclophosphamide can affect fertility and cannot be used during pregnancy, so rituximab is often preferred for people who may want children. Steroids act fast but cause weight gain, high blood sugar, bone thinning and infections with long use, so current regimens taper them more quickly than in the past. For people with severe kidney failure, plasma exchange, a procedure that filters the blood, is sometimes added, weighed against a higher risk of serious infection. Avacopan (Tavneos), a capsule that blocks complement (a part of the immune system that drives inflammation in this disease), was approved in 2021 as an add-on treatment for severe GPA and MPA. In 2026 the FDA proposed withdrawing its approval after finding that results of the main trial had been altered. It remains on the market while a final decision is made, and it can cause serious, sometimes fatal, liver injury. Anyone taking it should talk with their specialist about whether to continue. For maintenance, rituximab infusions every four to six months are the usual choice, with azathioprine or methotrexate (oral immune-suppressing medicines) as alternatives. Maintenance typically lasts about two to four years, balancing relapse risk against infection risk. EGPA is treated somewhat differently: milder disease may be treated with steroids plus mepolizumab (Nucala), an injected antibody that lowers eosinophils, while severe disease is treated like GPA and MPA. Because these medicines weaken the immune system, care also includes protection against their effects: an antibiotic (often low-dose trimethoprim-sulfamethoxazole) to prevent a serious pneumonia called Pneumocystis, recommended vaccines, screening for hepatitis B before rituximab, and measures to protect bone health.

What to Expect

ANCA-associated vasculitis is usually a long-term condition. The first months are often the hardest: frequent appointments, blood and urine tests, infusions, and the side effects of higher steroid doses. As the disease comes under control, treatment becomes less intensive and many people return to work and their usual activities, though fatigue can linger. The outlook has changed dramatically. Before modern treatment the disease was usually fatal, but most people now reach remission, and many stay well for years. Relapses still happen, more often in GPA than in MPA, which is why monitoring continues even when someone feels well. Some people are left with lasting effects from damage that occurred before treatment took hold, such as reduced kidney function, hearing loss or nerve pain. A minority develop kidney failure needing dialysis, and kidney transplant is an option once the disease has been in stable remission. Infection is a real risk during treatment and is a leading cause of serious illness in people with this condition, so learning which signs to report matters. Living with a rare, unpredictable illness can be stressful, and education, psychological support and patient support groups can help.

When to Seek Help

See a clinician if you have a combination of symptoms that keep coming back or will not settle, such as long-lasting sinus problems, nasal crusting or discharge, hearing changes, a red painful eye, numbness or weakness, and fatigue or weight loss, especially if a urine test shows blood or protein. If you already have the condition, tell your care team if symptoms return or treatment seems to be working less well. If you are on treatment, call your care team promptly for a fever or other signs of infection, since immune-suppressing medicines can let infections become serious quickly. Coughing up blood, or new or rapidly worsening shortness of breath, can mean bleeding in the lungs and needs emergency care the same day; call 911 if breathing is severely difficult.

Questions to Ask Your Doctor

  1. 1.Which type of ANCA-associated vasculitis do I have, and which organs are affected?
  2. 2.What are the goals of my induction and maintenance treatment, and how long is each phase likely to last?
  3. 3.How will we watch for a relapse, and which tests will show whether my kidneys and lungs are recovering?
  4. 4.What can I do to lower my risk of infection and steroid side effects while I am on treatment?
  5. 5.Is there any lasting organ damage, and what does that mean for my long-term care?

Last reviewed • Oct 2026

Educational content, not medical advice.